Recombinant human adenovirus type 5 (Sunway Biotech)

DUBLIN, Dec. 20, 2022 /PRNewswire/ -- The "Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global cancer immunotherapy market encompasses a broad range of applications, in which oncolytic virus immunotherapy is playing a vital role in overall development. Report Highlights Global Oncolytic Virus Immunotherapy Therapy Market Overview Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028 Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials Patent Information On More Than 60 Therapies in Clinical Trials IMLYGIC, Oncorine, Delytact: Availability, Dosage, and Price Analysis Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment Oncolytic Virus Immunotherapy Application By 10 Cancer Recent Strategic Partnerships, Collaborations, Mergers and Acquisitions The therapy involves a very basic thread of using viruses for targeting cancer cells and harnessing the natural as well as the destructive power of the immune system against the cancer cells. In a very short period of time, the clinical outcome associated with the therapy has laid down the foundation for the over-achieving future of the therapy. The therapy market is estimated to get recognized as a necessity in the overall cancer therapeutics market where old and traditional therapies available are not successful in declining the increasing mortality rate across the globe. Researchers have been successful in modifying the basic immunotherapy strategy by introducing the benefits of viruses in targeting the host cells. Beyond the excellent capacity of the virus to get incorporated into the host cell, the therapeutic introduction of the virus in cancer therapeutics is providing enormous amounts of opportunities that were somehow lacking in the overall cancer therapeutics market for a prolonged period of time. The future approval of the oncolytic virus therapy against a wide range of cancer types is believed to strengthen the pharmaceutical industry to reach the revenue sales that have not been recorded for any of the cancer therapy drugs. The strong link of the therapy with the clinical pipeline and the future timeframe which is about to justify the applications of the therapy are observed to overcome the challenges that the researchers have been facing in terms of resistance development, off-targeting, and adverse side effects. Amid the growth of other cancer therapies in the cancer therapeutics market, oncolytic virus therapy soon is going to deliver significant revolution and growth. The unimaginable applications of the therapy and the orientation of the government bodies towards expanding the clinical trial market of the same is estimated to develop the market as a dominant one for millions of patients who haven't received any benefits from the available therapies. The entry of oncolytic virus therapy into the market horizon is estimated to provide enormous healthcare opportunities to patients who have been struggling with cancer for a prolonged period of time. As per the report findings, the overall appreciation that the therapy has achieved in the such a shorter time period is poised to incline the therapy towards substantial growth. In the coming time period, the therapy market is believed to deliver promising trends and opportunities for researchers working in different biopharmaceutical companies and research centers, with hundreds of driving forces driving the market through various complications. On the regulatory side, the legislations of developed pharmaceutical countries are also inclining towards boosting the researchers to expand the market applications and drive the competition in the right direction, where appropriate funds for clinical research activities are acting as the catalyst for the therapy. The unlimited applications found within the therapy and the clinical platform for the same is estimated to move the therapy toward success at an unprecedented rate in the coming years. Key Topics Covered: 1. Introduction to Oncolytic Virus: Trail From Genesis To Biogenetics 2. Primer of Virotherapy in Malignancies 2.1 Oncolytic Viruses Towards Cancer 2.2 Approaches for Targeting Tumor Cells 2.3 Viral Oncolysis Mechanism of Action 3. Oncolytic Viruses Immunotherapy Overview 3.1 Stimulation of Antitumor Immune Responses 3.2 Oncolytic Viruses as Cancer Vaccines 4. Potential Oncolytic Virus Immunotherapy for Cancers 4.1 Breast Cancer 4.2 Lung Cancer 4.3 Prostate Cancer 4.4 Melanoma 4.5 Brain Tumor 4.6 Blood Cancer 4.7 Colorectal Cancer 4.8 Bladder Cancer 4.9 Pancreatic Cancer 4.10 Head and Neck Cancer 5. Global Oncolytic Virus Immunotherapy Therapy Market Overview 5.1 Preface Towards Oncolytic Virus Arcade 5.2 Market Aspects of Approved Oncolytic Viruses 6. Imlygic (Talimogene laherparepvec): Clinical and Pricing Insight 6.1 Clinical Overview 6.2 Availability, Dosage and Price Analysis 7. Oncorine (H101): Clinical and Pricing Insight 7.1 Clinical Overview 7.2 Availability, Dosage and Price Analysis 8. Delytact (DS 1647): ): Clinical and Pricing Insight 8.1 Clinical Overview 8.2 Availability, Dosage and Price Analysis 9. Global Oncolytic Virus Immunotherapy Clinical Pipeline Overview 9.1 By Phase 9.2 By Company 9.3 By Country 9.4 By Indication 9.5 By Patient Segment 10. Global Oncolytic Viruses Clinical Pipeline By Company, Indication and Phase 10.1 Research 10.2 Preclinical 10.3 Phase-I 10.4 Phase-I/II 10.5 Phase-II 10.6 Phase-III 10.7 Registered 11. Strategic Partnerships, Collaborations, Mergers and Acquisitions to Advance the Oncolytic Virus Therapy Market 11.1 Estrella Biopharma Signs Deal To Merge With Blank Check Company 11.2 ABL and Imugene Announce Partnership to Advance Oncolytic Virus Candidates Into Late Clinical Trial Phase 11.3 TILT Biotherapeutics and Merck to Undergo Clinical Trial Collaboration for Refractory Non-Small Cell Lung Cancer 11.4 Virogin Biotech and MD Anderson Announce Strategic Collaboration For Treating Advance Cancers 11.5 ABL Signs Pact With KaliVir On Oncolytic Viruses 11.6 Targovax Announces Clinical Collaboration With Agenus For Melanoma Trial 11.7 KaliVir Announces Exclusive Agreement With Roche For Developing Novel Oncolytic Viruses 11.8 ImmVira and Roche Enter Cooperation Agreement For Evaluating Novel Combination For Cancer Therapy 11.9 Calidi and Edoc Agree On Merger To Revolutionize Oncolytic Viral Therapies 11.10 Synthetic Biologics Completes Acquisition of VCN Biosciences 11.11 VacV Biotherapeutics Exits Stealth With $3 Million Investment 11.12 Targovax Enters Research Collaboration With Karolinska Institutet Professor 11.13 Transgene and PersonGen To Collaborate To Evaluate New Combination Therapy Against Solid Tumors 11.14 Lokon Pharma Initiates Collaboration With To Develop Novel Cancer Therapeutics 11.15 Bionaut Labs and Candel Therapeutics Announce Collaboration For Novel Targeting Mechanism For Oncolytic Virus Delivery 11.16 Imugene and Eureka Announce Strategic Collaboration to Accelerate Oncolytic Virus and T-Cell Therapy Combination 11.17 CG Oncology Enters Into Clinical Trial Collaboration With Roche For Novel Oncolytic Immunotherapy Combination 11.18 Imugene Enters Into Exclusive Strategic Partnership With Celularity To Develop Novel Combination For Treating Solid Tumors 12. Global Oncolytic Virus Immunotherapy Market Dynamics 12.1 Favorable Market Parameters 12.2 Growth Inhibitors 13. Global Oncolytic Virus Immunotherapy Market Future Outlook 14. Competitive Landscape 14.1 AdCure Bio 14.2 Beijing SyngenTech 14.3 BioVex Inc. 14.4 Calidi Biotherapeutics 14.5 Genelux Corporation 14.6 Immvira Pharma 14.7 Jennerex Biotherapeutics 14.8 KaliVir 14.9 Lokon Pharma 14.10 Merck 14.11 Oncolys BioPharma 14.12 Oncorus 14.13 PsiOxus Therapeutics 14.14 Seneca Therapeutics 14.15 Shanghai Sunway Biotech 14.16 Takara Bio 14.17 Targovax 14.18 TILT Biotherapeutics 14.19 Transgene 14.20 Virogin Biotech For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

One of the biggest threats to human health and life has always been cancer, and as instances rise each year, so do the financial and emotional burdens placed on patients and their families. While conventional treatment methods have been helpful in improving the patients’ survival and quality of life, little effect has been seen in patients with advanced forms of cancer, generating the need for new approaches for cancer management. In the last six decades, the discovery of oncolytic viruses has changed the research paradigm for cancer therapy and has emerged as one of the newest strategies for cancer management. The approval of three oncolytic viruses has further helped in grabbing the attention of pharmaceutical companies and researchers alike, which has been the main driver in promoting their growth. Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028 Report Overview: Global Oncolytic Virus Immunotherapy Therapy Market Overview Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1 Billion By 2028 Insight On More Than 180 Oncolytic Virus Immunotherapies In Clinical Trials Patent Information On More Than 60 Therapies in Clinical Trials IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis Oncolytic Virus Immunotherapy Clinical Pipeline By Country, Phase, Indication, Organization, Patient Segment Oncolytic Virus Immunotherapy Application By 10 Cancer Recent Strategic Partnerships, Collaborations, Mergers and Acquisitions Download Report: Oncolytic viruses, naturally or through genetic modifications, have the capacity to proliferate in cancer cells. The modality has been studied extensively in several types of cancer, and some of these OVs have also gained approval by regulatory bodies. Globally, Oncorine was the first oncolytic virus to be granted approval by a regulatory authority. It was approved in China in 2005 for the treatment of head and neck cancer. This was followed by the approval of Imlygic for treating melanoma by the FDA and EMA and is the only OV to have those approvals. More recently, Delytact received a conditional approval by Japan’s drug approval authority in June, 2021. The drug was given approval for the treatment of malignant glioma, which was a big milestone because no other OV has gained approval for brain cancer, demonstrating that the blood-barrier crossing abilities of these viruses can be utilized for the treatment of cancers of the brain. Delytact was developed jointly by Daichii Sankyo and Professor Tomoki Todo of the University of Tokyo’s Institute of Medical Science. It is a herpes simplex virus type 1 (HSV-1) which has been mutated to replicate exclusively in cancer cells. Oncolytic virus selectively replicate in cancer cells until cell death occurs post which, antitumor antigens produced by the virus are released in the tumor environment which allows the immune system to attack cancer cells by identifying the cancer antigens. It was granted a Sakigake fast-track designation in 2016 which was followed by an orphan regenerative medical product designation for malignant glioma in July, 2017. It has been given a 7 years limited time approval by the PMDA under which the company has to verify the safety and efficacy of the drug in the next seven years, after which the drug can be fully approved in the market. This approval was based in the data from a single-arm phase II trial which showed that treatment with Delytact improved the chances of survival in patients with residual or recurrent glioblastoma previously treated with radiotherapy and chemotherapy with Temodar (temozolomide). Regardless of the approval being only for a limited time, approval of Delytact given hope to many patients suffering from gliomas and also to researchers and pharmaceutical companies having drugs for brain cancer under development. Candel Therapeutics, DNAtrix and Transgene are some other companies apart from Daichii Sankyo who have OVs against brain cancer in clinical trials. While all these clinical trials are in early stages, the pursuers are expecting optimistic results for their respective drugs and from the approval process based on the designations held by Delytact and the conditions of its approval. Oncolytic viruses have been a lot of attention lately, mostly by the approval of Amgen’s Imlygic, which is among the handful of major pharmaceutical companies working on oncolytic virotherapy. The commercial performance of all these drugs will further fuel the development activities and allow the entry of more drugs in the development pipeline and the market. Contact: Neeraj Chawla Kuick research Research Head +91-981410366 neeraj@kuickresearch.com